



Admedus Limited
ABN 35 088 221 078

REGISTERED OFFICE:
26 Harris Road
Malaga Western Australia 6090

Customer Service:
T 1300 550 310
F 1300 880 398

International:
T +61 (0)8 9266 0100
F +61 (0)8 9266 0199
E info.au@admedus.com
www.admedus.com

COMPANY ANNOUNCEMENT

Brisbane, Australia, 7 July, 2017

UPDATE ON THE CARDIOCEL® 3D PRODUCT LAUNCH

Admedus Limited (ASX:AHZ) today announced that it is moving from its premarket program to an expanded access program for CardioCel® 3D to ensure that the Company gathers as much useful case data as possible before the product's commercial introduction. Admedus is already working in four key reference centers in the United States and this will increase to 10 prior to full launch later this year.

"The progress to date on CardioCel 3D has been excellent and the current user feedback from our surgeons is extremely promising," says Admedus CEO Wayne Paterson. "This is a pioneering new product – applying our proprietary ADAPT® technology – for an important market segment, and so we are making every effort to launch CardioCel® 3D right from the start in a phased and prudent way working closely with physicians."

For more information, please contact:

Australia and New Zealand

Admedus Limited
Barb Ferres, Senior Communications Advisor
Tel: +61 7 3152 3216
communications@admedus.com

North America

Signal Leadership Communication Inc.
Bob Pickard
Tel: +1 (647) 822 1000
bob.pickard@signaleadership.com

About Admedus Limited

Admedus (ASX:AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com